Protalex (OTCMKTS:PRTX) and Auxly Cannabis Group (OTCMKTS:CBWTF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.
Earnings & Valuation
This table compares Protalex and Auxly Cannabis Group’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Auxly Cannabis Group||$580,000.00||566.96||-$51.68 million||N/A||N/A|
This table compares Protalex and Auxly Cannabis Group’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Auxly Cannabis Group||-652.13%||-21.42%||-15.06%|
Institutional & Insider Ownership
0.2% of Protalex shares are held by institutional investors. Comparatively, 0.0% of Auxly Cannabis Group shares are held by institutional investors. 80.0% of Protalex shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Protalex has a beta of -1.03, indicating that its share price is 203% less volatile than the S&P 500. Comparatively, Auxly Cannabis Group has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500.
This is a breakdown of recent recommendations for Protalex and Auxly Cannabis Group, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Auxly Cannabis Group||0||0||0||0||N/A|
Protalex beats Auxly Cannabis Group on 6 of the 8 factors compared between the two stocks.
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.
About Auxly Cannabis Group
Auxly Cannabis Group Inc. operates as a cannabis streaming company. It provides funding for cannabis production; and holds contractual rights and minority equity interest relating to the operation of cannabis facilities. The company was formerly known as Cannabis Wheaton Income Corp. and changed its name to Auxly Cannabis Group Inc. in June 2018. Auxly Cannabis Group Inc. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Receive News & Ratings for Protalex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalex and related companies with MarketBeat.com's FREE daily email newsletter.